The U.S. Food and Drug Administration (FDA) issued a warning on December 17, 2024, concerning potential dangers associated with Zoetis's dog pain drug, Librela. The agency stated it had reviewed over 3,600 cases of side effects.
These reported side effects included deaths in dogs that had been administered Librela. This warning could impact veterinarian prescribing patterns and pet owner confidence in the medication.
Librela is a significant product in Zoetis's osteoarthritis pain franchise, and such regulatory scrutiny may lead to increased caution in its use.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.